Ezetimibe in Heart Transplantation: Initial Experience

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2389-2392

  Moro, J ^a   Almenar, L ^a   Martinez Dolz L ^a   Izquierdo, M ^a   Aguero J ^a   Sanchez Lazaro I ^a   Ortiz, V ^a   Salvador, A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; STEROID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 34548691035     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.043     Document Type: Article

References (24)

1. Lidenferld J., Page R.L., Zolty R., et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation 111 (2005) 113
2. Law Y.M., Yim R., Agatisa P., et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 25 (2006) 276
3. Quaschning T., Mainka T., Nauck M., et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 71 (1999) S235
4. Ichimaru N., Takahara S., Kokado Y., et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158 (2001) 417
5. Akhlaghi F., Jackson C.H., Parameshwar J., et al. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 73 (2002) 1258
6. Fernandez-Miranda C., Guijarro C., de la Calle A., et al. Lipid abnormalities in stable liver transplant recipients-effects of cyclosporin, tacrolimus, and steroids. Transpl Int 11 (1998) 137
7. Grigioni F., Carigi S., Potena L., et al. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc 38 (2006) 1507
8. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736
9. Mahle W.T., Vincent R.N., Berg A.M., et al. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 24 (2005) 63
10. Mehra M.R., and Raval N.Y. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 36 (2004) 1539
11. Genest J. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Can J Cardiol 22 (2006) 863
12. Robinson J.G., and Davidson M.H. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 4 (2006) 461
13. Patel J.V., and Hughes E.A. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract 60 (2006) 914
14. Koshman S.L., Lalonde L.D., Burton I., et al. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 39 (2005) 1561
15. Bilchick K.C., Henrikson C.A., Skojec D., et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 148 (2004) 200
16. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 (2004) S187
17. Pinney S.P., and Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 19 (2004) 170
18. Almenar L. Spanish Heart Transplantation Registry. 16th official report of the Spanish Society of Cardiology Working Group on Heart Failure, Heart Transplantation, and Associated Therapies. Rev Esp Cardiol 58 (2005) 1310
19. Eisen H.J., Tuzcu E.M., Dorent R., et al., RAD B253 Study Group. Everolimus for the prevention af allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847
20. Vitko S., Margreiter R., Weimar, et al. Three-year efficacy and safety results from a study of everolimus versus mycophemolate mofetil in de novo renal transplant patients. Am J Transplant 5 (2005) 2521
21. Lorber M.I., Mulgaonkar S., Butt K.M., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 (2005) 244
22. Vitko S., Margreiter R., Weimar, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (2004) 1532
23. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271
24. Kakiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Diseases Work Group of the National Kidney Foundation Kideny Disease Outcomes Quality Initiative. Am J Transplant 4 suppl 7 (2004) 13